Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 ...

So many soldiers and families suffered and sacrificed so much. It is important that they be remembered," the veteran's niece ...

T-cell lymphoma has remained an exceptionally challenging disease with limited therapeutic advances for far too long,” said Nicholas Siciliano, Ph.D., Chief Executive Officer of Vittoria ...

CFMoto has unveiled a prototype for a highly ambitious V4-powered motorcycle that's sure to turn heads with its distinctive ...

The group stage of the 2025 NBA Cup will pick up the pace Friday night with an 11-game slate. Here's where the Celtics stand ...

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating ...

Online romance has migrated from actual dating apps to… everywhere else. Here we break down the romantic potential of the ...

ASX device and diagnostic companies are intensifying their measures to expedite product rollouts and approvals in the US.

Anika Therapeutics, Inc. (NASDAQ: ANIK) Q3 2025 Earnings Call Transcript November 5, 2025 Anika Therapeutics, Inc. misses on ...

Toyota recalls more than 1 million vehicles worldwide due to rear camera error; MPV series receives 'huge' incentives at the ...

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, ...

These findings for lorundrostat will provide the foundation for an NDA submission which we anticipate submitting near the end of 2025 or during the first quarter of 2026,” stated Jon Congleton, Chief ...